Alixia Analysis: $2M Raised
What is Alixia?
Alixia develops preclinical therapeutics aimed at disrupting tumor ecosystems and overcoming drug resistance in solid tumors. The company also describes a broader portfolio for aging, neurodegeneration, inflammation, and immune dysregulation. Its site says the team combines scientists, clinicians, and drug developers, with advisors linked to UCSF and Harvard.
Location
953 Indiana St, San Francisco, California 94107, United States
Employees
1-10
Founded
2022
Revenue
$1M
Product Features & Capabilities
- tumor ecosystem disruptors, compounds targeting metabolic and inflammatory triggers, therapeutic portfolio addressing cancer, aging, neurodegeneration, inflammation, immune dysregulation
How much Alixia raised
1 - $1,825,445
July 23, 2024Lead Investor: Not specified
Who are the founders of Alixia
OM
Olof Mollstedt
Co-founder & Co-CEO
HC
Helen Chen, Ph.D.
Co-founder & Co-CEO
Investors
- Y Combinator
- IndieBio
- Eight Capital
- Endless Frontier Labs
- MCMA Ventures
- Gaingels
Market Focus
Alixia primarily focuses on the biotechnology and pharmaceutical industry, specifically targeting cancer treatment by addressing drug resistance and studying tumor interactions to develop therapeutic innovations.
Business Model
Focus on therapeutic innovations; revenue from funding and partnerships in cancer research.
Competitors Overview
Alixia operates in the cancer therapeutics market, focusing on addressing drug resistance through innovative therapies targeting the tumor ecosystem. Its main competitors include:
-
ORIC Pharmaceuticals: This company develops therapies specifically aimed at overcoming cancer resistance, enhancing the effectiveness of existing treatments. Their focus on innovative solutions to drug resistance aligns closely with Alixia's mission.
-
Carrick Therapeutics: A clinical-stage biopharmaceutical company that aims to improve patient outcomes in oncology. They are focused on developing therapies that can address various cancer types, including those resistant to current treatments.
-
Cybrexa Therapeutics: This company utilizes a platform technology for antigen-independent targeting of tumors, which may provide advantages in penetrating deep tissue and addressing drug resistance.
-
Kura Oncology: They focus on targeted therapies that are designed to be well-tolerated and effective, aiming for long-lasting remission in cancer patients.
-
Pacylex Pharmaceuticals: Developing a first-in-class oral cancer therapy with a novel mechanism of action, they aim to address drug resistance in a unique way.
-
TOLREMO therapeutics AG: This Swiss biotechnology company is working on resistance-breaking therapies designed to eliminate treatment-resistant cancer cells.
These competitors share a focus on innovative approaches to combat cancer drug resistance, but each has unique mechanisms and strategies that differentiate them from Alixia.
See something that needs updating? Suggest edits to this profile.